Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
«Мирена» – как эффективный и приемлемый метод контрацепции. Анализ побочных реакций.
«Мирена» – как эффективный и приемлемый метод контрацепции. Анализ побочных реакций.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Coleman M. Levonorgestrel-releasing IUD – more than only a contraceptive method. Aust NZ Obstet Gynaecol 1997; 37 (2).
2. Critchley HO, Wang H, Kelly RW et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of the women using a levonorgestre-releasing intrauterine system. Human Reprod 1998; 13 (5): 1210–7.
3. Critchley HOD, Wang H, Jones R et al. Morphological
and functional features of endometrial decidualisation following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998; 13 (5): 1218–24.
4. Gerber B, Reimer T, Krause A et al. Levonorgestrel-releasing intrauterine devices. Lancet 2001; 10: 357.
5. Goran Rybo, Kerstin Andersson, Viveca Odlind. Hormonal intrauterine devices. Ann Med 1993; 25: 143–7.
6. Kunz J. Levonorgestrel releasing intrauterine spiral-contraception – therapeutic indications. Schweiz Rundsch Med Prax 2001; 90: 442–52.
7. Lu SM. Effect of levonorgestrel intrauterine device on human endometrial estrogen and progesterone receptors. Chung-Hua-Fu-Chan-Ko-Tsa-Chin 1991; 26 (5): 293–4.
8. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001; 19 (4): 355–64.
9. Mirena. Product monograph. Shering AG. 2002.
10. Oliveira da Silva M, Costa M. Reasons, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. The Europ J Contracep Reprod Health Care 1999; 4: 21.
11. Ronnerdag M. Health effects of long-term use of the LNG-IUS. Abstracts book. Mirena – effective contraception with health benefits. 2001; 10–1.
12. Ronnerdag M, Odlind V. Health effect of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999; 78 (8): 716–21.
13. Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynecol Forum 1998; 3 (3): 11–4.
14. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of the intrauterinelevonorgestrel-delivery. Hum Reprod 2001; 15 (3): 173–81.
15. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996; 15 (6): 430–40.
16. Wildemeersch D, Schacht E, Thiery M et al. Intrauterine contraception in the year 2001: can intrauterine devices use be revived with new improved contraceptive technology? The Eur J Contacep Reprod Health Care 2000; 5: 295–304.
17. Zhou J, Dsupin BA, Gindice LC et al. Insulin-like growth factor (IGF) IGF binding protein and IGF receptor gene expression in human endometrium. J Con Endocrinol Metab 1994; 79: 1723–34.
2. Critchley HO, Wang H, Kelly RW et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of the women using a levonorgestre-releasing intrauterine system. Human Reprod 1998; 13 (5): 1210–7.
3. Critchley HOD, Wang H, Jones R et al. Morphological
and functional features of endometrial decidualisation following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998; 13 (5): 1218–24.
4. Gerber B, Reimer T, Krause A et al. Levonorgestrel-releasing intrauterine devices. Lancet 2001; 10: 357.
5. Goran Rybo, Kerstin Andersson, Viveca Odlind. Hormonal intrauterine devices. Ann Med 1993; 25: 143–7.
6. Kunz J. Levonorgestrel releasing intrauterine spiral-contraception – therapeutic indications. Schweiz Rundsch Med Prax 2001; 90: 442–52.
7. Lu SM. Effect of levonorgestrel intrauterine device on human endometrial estrogen and progesterone receptors. Chung-Hua-Fu-Chan-Ko-Tsa-Chin 1991; 26 (5): 293–4.
8. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001; 19 (4): 355–64.
9. Mirena. Product monograph. Shering AG. 2002.
10. Oliveira da Silva M, Costa M. Reasons, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. The Europ J Contracep Reprod Health Care 1999; 4: 21.
11. Ronnerdag M. Health effects of long-term use of the LNG-IUS. Abstracts book. Mirena – effective contraception with health benefits. 2001; 10–1.
12. Ronnerdag M, Odlind V. Health effect of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999; 78 (8): 716–21.
13. Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynecol Forum 1998; 3 (3): 11–4.
14. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of the intrauterinelevonorgestrel-delivery. Hum Reprod 2001; 15 (3): 173–81.
15. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996; 15 (6): 430–40.
16. Wildemeersch D, Schacht E, Thiery M et al. Intrauterine contraception in the year 2001: can intrauterine devices use be revived with new improved contraceptive technology? The Eur J Contacep Reprod Health Care 2000; 5: 295–304.
17. Zhou J, Dsupin BA, Gindice LC et al. Insulin-like growth factor (IGF) IGF binding protein and IGF receptor gene expression in human endometrium. J Con Endocrinol Metab 1994; 79: 1723–34.
2. Critchley HO, Wang H, Kelly RW et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of the women using a levonorgestre-releasing intrauterine system. Human Reprod 1998; 13 (5): 1210–7.
3. Critchley HOD, Wang H, Jones R et al. Morphological
and functional features of endometrial decidualisation following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998; 13 (5): 1218–24.
4. Gerber B, Reimer T, Krause A et al. Levonorgestrel-releasing intrauterine devices. Lancet 2001; 10: 357.
5. Goran Rybo, Kerstin Andersson, Viveca Odlind. Hormonal intrauterine devices. Ann Med 1993; 25: 143–7.
6. Kunz J. Levonorgestrel releasing intrauterine spiral-contraception – therapeutic indications. Schweiz Rundsch Med Prax 2001; 90: 442–52.
7. Lu SM. Effect of levonorgestrel intrauterine device on human endometrial estrogen and progesterone receptors. Chung-Hua-Fu-Chan-Ko-Tsa-Chin 1991; 26 (5): 293–4.
8. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001; 19 (4): 355–64.
9. Mirena. Product monograph. Shering AG. 2002.
10. Oliveira da Silva M, Costa M. Reasons, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. The Europ J Contracep Reprod Health Care 1999; 4: 21.
11. Ronnerdag M. Health effects of long-term use of the LNG-IUS. Abstracts book. Mirena – effective contraception with health benefits. 2001; 10–1.
12. Ronnerdag M, Odlind V. Health effect of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999; 78 (8): 716–21.
13. Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynecol Forum 1998; 3 (3): 11–4.
14. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of the intrauterinelevonorgestrel-delivery. Hum Reprod 2001; 15 (3): 173–81.
15. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996; 15 (6): 430–40.
16. Wildemeersch D, Schacht E, Thiery M et al. Intrauterine contraception in the year 2001: can intrauterine devices use be revived with new improved contraceptive technology? The Eur J Contacep Reprod Health Care 2000; 5: 295–304.
17. Zhou J, Dsupin BA, Gindice LC et al. Insulin-like growth factor (IGF) IGF binding protein and IGF receptor gene expression in human endometrium. J Con Endocrinol Metab 1994; 79: 1723–34.
________________________________________________
2. Critchley HO, Wang H, Kelly RW et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of the women using a levonorgestre-releasing intrauterine system. Human Reprod 1998; 13 (5): 1210–7.
3. Critchley HOD, Wang H, Jones R et al. Morphological
and functional features of endometrial decidualisation following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998; 13 (5): 1218–24.
4. Gerber B, Reimer T, Krause A et al. Levonorgestrel-releasing intrauterine devices. Lancet 2001; 10: 357.
5. Goran Rybo, Kerstin Andersson, Viveca Odlind. Hormonal intrauterine devices. Ann Med 1993; 25: 143–7.
6. Kunz J. Levonorgestrel releasing intrauterine spiral-contraception – therapeutic indications. Schweiz Rundsch Med Prax 2001; 90: 442–52.
7. Lu SM. Effect of levonorgestrel intrauterine device on human endometrial estrogen and progesterone receptors. Chung-Hua-Fu-Chan-Ko-Tsa-Chin 1991; 26 (5): 293–4.
8. Luukkainen T, Pakarinen P, Toivonen J. Progestin-releasing intrauterine systems. Semin Reprod Med 2001; 19 (4): 355–64.
9. Mirena. Product monograph. Shering AG. 2002.
10. Oliveira da Silva M, Costa M. Reasons, myths and fantasies: preliminary data and reflections about the Portuguese experience with LNG-IUS-induced hypomenorrhea. The Europ J Contracep Reprod Health Care 1999; 4: 21.
11. Ronnerdag M. Health effects of long-term use of the LNG-IUS. Abstracts book. Mirena – effective contraception with health benefits. 2001; 10–1.
12. Ronnerdag M, Odlind V. Health effect of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999; 78 (8): 716–21.
13. Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynecol Forum 1998; 3 (3): 11–4.
14. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of the intrauterinelevonorgestrel-delivery. Hum Reprod 2001; 15 (3): 173–81.
15. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Safety 1996; 15 (6): 430–40.
16. Wildemeersch D, Schacht E, Thiery M et al. Intrauterine contraception in the year 2001: can intrauterine devices use be revived with new improved contraceptive technology? The Eur J Contacep Reprod Health Care 2000; 5: 295–304.
17. Zhou J, Dsupin BA, Gindice LC et al. Insulin-like growth factor (IGF) IGF binding protein and IGF receptor gene expression in human endometrium. J Con Endocrinol Metab 1994; 79: 1723–34.
Авторы
Ф.С.Ревазова, В.Н.Прилепская
ФГУ «НЦ акушерства, гинекологии и перинатологии им. акад. РАМН В.Н.Кулакова»
(дир. – акад. РАМН Г.Т.Сухих), Москва
ФГУ «НЦ акушерства, гинекологии и перинатологии им. акад. РАМН В.Н.Кулакова»
(дир. – акад. РАМН Г.Т.Сухих), Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.